Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/13/23
End: 03/31/27
Due: 03/31/28
Phase: N/A
Priority: Normal
Start: 07/22/19
End: 08/31/25
Due: 08/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) | NCT05846516 | Amal Therapeutics | user2@example.com | None | 2023-03-13 | 2027-03-31 | 2028-03-31 | - | - | 2025-07-14 |
| Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer | NCT04046445 | Amal Therapeutics | user2@example.com | None | 2019-07-22 | 2025-08-31 | 2026-08-31 | - | - | 2025-07-14 |